Mi2000 Totally Implantable Cochlear Implant (Mi2000 TICI)
Key facts
- Who runs it
- MED-EL Elektromedizinische Geräte GmbH
- Where
- Austria, Belgium, Germany, and Poland6 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 7 Jun 2024
- Ended
- 24 Sept 2025
- Type of study
- Interventional
- Treatments tested
- Mi2000 TICI
- Record updated
- 1 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Minimum age of eighteen (18) years at time of enrolment
- Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4)
- Post-lingual onset of deafness
- No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
- A maximum score of 50% on a word test in the language of the test centre in the ear to be implanted in the best aided condition
- Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
- Functional auditory nerve
- General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
- Pre-operative assessment according to the local professional standards
- Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant centre for regular speech processor programming, assessment sessions and training
- Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
- Evidence of up-to-date vaccinations against meningitis, as per recommendations by the applicable national body
- Signed and dated informed consent before the start of any study-specific procedure
Who cannot take part
- Previously having received an implant on the location chosen for placing the cochlear implant
- Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear
- The individual is known to be intolerant of the materials used in the implant or other required accessories including medical grade silicone, parylene C, titanium, platinum iridium, platinum, stainless chromate steel, thermoplastic elastomere (TPE-S), thermoplastic elastomere (SEBS), mixture of polycarbonate and acrylonitrile-butadiene-styrol polymer (PC/ABS), polyamide, liquid crystal polymer, silicone and polyurethane-coated silicone rubber)
- Medical contra-indications to middle ear and/or inner ear surgery, and/or anaesthesia
- Participation in other pharmacological clinical trials within four weeks prior to enrolment
- Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI
- External or middle ear infections are present
- History of vestibular schwannoma
- Unstable Meniere's disease
- Epilepsy not responding to treatment
- Known intellectual disability and/or psychological diseases
- Women of childbearing age not reporting to use effective contraception
- Lack of compliance with any inclusion criterion
- Women being pregnant or nursing
- Absence of cochlear development
- The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway
- The tympanic membrane is perforated in the ear to be implanted
- Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)
- The psychological status of the individual is unstable
- The individual has unrealistic expectations
- Acute cholesteatoma
- Auditory Neuropathy
- Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation
- Anything that, in the opinion of the Investigator, would place the subject at increased risk; preclude the subject's full compliance with or completion of the study
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to test the Mi2000 Totally Implantable Cochlear Implant in a population of candidates for a cochlear implant. The main question it aims to answer is, whether the device is able to improve speech perception compared to the pre-operative score.
Read full original descriptionShow less
Participants will undergo cochlear implantation and fitting, and will be asked to perform the following tests pre- and post-operatively:
* Word test in quiet * Sentence test in noise * Audiograms * Health Utilities Index 2 and 3 (HUI2\&3), a generic quality-of-life questionnaire * Nijmengen Cochlear Implant Questionnaire (NCIQ), a disease specific quality-of life questionnaire * Speech, Spatial and Qualities of Hearing Scale (SSQ12), a disease specific questionnaire * Hearing Implant Sound Quality Index (HISQUI19), a sound quality questionnaire
The group in the trial
- Interventional ArmTreatment being tested
Implantation with Mi2000 TICI
Treatment: Mi2000 TICI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Mi2000 Totally Implantable Cochlear Implant (Mi2000 TICI): Pivotal Study
- Record updated
- 1 October 2025